Efonidipine

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels. It has also been studied in atherosclerosis and acute renal failure.

Synonyms:

2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate;

Efonidipine HCl;

3-(benzyl-(phenyl)amino)ethyl-5-(5,5-dimethyl-2-oxo-1,3-dioxaphosphorinane-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine;

Properties:

Density: 1.3g/cm3

Boiling Point: 746.9ºC at 760mmHg

Flash Point: 405.5ºC

Calcium Channel Inhibitors Related Products:

Manidipine 2HCl; Felodipine; Nisoldipine; Fasudil HCl; Cilnidipine; Dronedarone HCl; Clevidipine Butyrate; Amlodipine; ISX-9 (Isoxazole 9); Gabapentin; MRS 1845; Fantofarone; Suvecaltamide (MK-8998); Ziconotide; Catharanthine Tartrate; Lercanidipine Hydrochloride; Bepridil hydrochloride

[1]. Ikeda K, et al. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Tohoku J Exp Med. 2011;224(4):263-71.

[2]. Nakano N, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010 May;51(3):188-92.